Growth regulation of prostatic stromal cells by prostate-specific antigen

Journal of the National Cancer Institute

Volumn 91, Issue 19, 1999, Pages 1663-1669

  Sutkowski, Debra M ^a   Goode, Robin L ^a   Baniel, Jack ^b   Teater, Carroll ^a   Cohen, Pinchas ^c   McNulty, Ann M ^a   Hsiung, Hansen M ^a   Becker, Gerald W ^a   Neubauer, Blake Lee ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN;

ARTICLE; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REGULATORY MECHANISM; STROMA CELL;

EID: 0033530292     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.19.1663     Document Type: Article

References (53)

1. Froesch ER, Schmid C, Schwander J, Zapf J. Action of insulin-like growth factors. Ann Rev Physiol 1985;47:443-67.
2. LeRoith D, Werner H, Burguera B, Roberts CT Jr, Mulroney S, Haramati A. The insulin-like growth factor family of peptides, binding proteins and receptors: their potential role in tissue regeneration. Adv Exp Med Biol 1992;321:21-8.
3. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev 1989;10:68-91.
4. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor I. Cancer Res 1993;53:1102-6.
5. De Mellow JS, Baxter R. Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun 1988;156:199-204.
6. Elgin RG, Busby WH Jr, Clemmons DR. An insulin-like growth factor (IGF) binding protein enhances the biologic response of IGF-I. Proc Natl Acad Sci U S A 1987;84:3254-8.
7. Drop SL, Schuller AG, Lindenbergh-Kortleve DJ, Groffen C, Brinkman A, Zwarthoff EC. Structural aspects of the IGFBP family. Growth Regul 1992; 2:69-79.
8. Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M, Binoux M. Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 15OK complex during pregnancy. J Clin Endocrinol Metab 1990;71:797-805.
9. Yamanaka Y, Wilson EM, Rosenfeld RG, Oh Y. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem 1997;272:30729-34.
10. Lamson G, Giudice LC, Cohen P, Liu F, Gargosky S, Muller HL, et al. Proteolysis of IGFBP-3 may be a common regulatory mechanism of IGF action in vivo. Growth Regul 1993;3:91-5.
11. Cohen P, Fielder PJ, Hasegawa Y, Frisch H, Giudice LC, Rosenfeld RG. Clinical aspects of insulin-like growth factor binding proteins. Acta Endocrinol (Copenh) 1991;124 Suppl 2:74-85.
12. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75:1046-53.
13. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979;17:159-63.
14. Ban Y, Wang MC, Watt KW, Loor R, Chu TM. The proteolytic activity of human prostate-specific antigen. Biochem Biophys Res Commun 1984; 123:482-8.
15. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1899-903.
16. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
17. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer [published erratum appears in N Engl J Med 1991;325: 1324]. N Engl J Med 1991;324:1156-61.
18. Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987;80:281-5.
19. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978;15:340-5.
20. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8:338-62.
21. Tenniswood M. Role of epithelial-stromal interactions in the control of gene expression in the prostate: an hypothesis. Prostate 1986;9:375-85.
22. Sherwood ER, Berg LA, Mitchell NJ, McNeal JE, Kozlowski JM, Lee C. Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. J Urol 1990;143:167-71.
23. Kassen A, Sutkowski DM, Ahn H, Sensibar JA, Kozlowski JM, Lee C. Stromal cells of the human prostate: initial isolation and characterization. Prostate 1996;28:89-97.
24. Sherwood ER, Berg LA, Mitchell NJ, McNeal JE, Kozlowski JM, Lee C. Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. J Urol 1990;143:167-71.
25. Sherwood ER, Berg LA, McEwan RN, Pasciak RM, Kozlowski JM, Lee C. Two-dimensional protein profiles of cultured stromal and epithelial cells from hyperplastic human prostate. J Cell Biochem 1989;40:201-14.
26. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A 1986;83:3166-70.
27. Dunnett CW. New tables for multiple comparisons with a control. Biometrics 1964;20:482-91.
28. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika 1965;52:591-611.
29. Peehl DM, Cohen P, Rosenfeld RG. The insulin-like growth factor system in the prostate. World J Urol 1995;13:306-11.
30. Berkel HJ. Cancer trends and health care [editorial]. CMAJ 1993;149: 569-70.
31. Grayhack JT, Kozlowski JM. Benign prostatic hyperplasia. In: Gillenwater JY, Grayhack JT, Howards SS, Duckett JU, editors. Adult and pediatric urology. Chicago (IL): Year Book Publishers; 1988. p. 1062-125.
32. Ohkawa H, Harigaya K. Effect of direct cell-to-cell interaction between the KM-102 clonal human marrow stromal cell line and HL-60 myeloid cell leukemic cell line on the differentiation and proliferation of the HL-60 cell line. Cancer Res 1987;47:2879-82.
33. Perris R, von Boxberg Y, Lofberg J. Local embryonic matrices determine region-specific phenotypes in neural crest cells. Science 1988;241:86-9.
34. Peres R, Betsholtz C, Westermark B, Heldin CH. Frequent expression of growth factors for mesenchymal cells in human mammary carcinoma cell lines. Cancer Res 1987;47:3425-9.
35. Weber JP, Oesterling JE, Peter CA, Partin AW, Chan DW, Walsh PC. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol 1989;141: 987-92.
36. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, et al. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LN-CaP. Prostate 1992;21:63-73.
37. Yang Y, Chisholm GD, Habib FK. The distribution of PSA, cathepsin-D, and pS2 in BPH and cancer of the prostate. Prostate 1992;21:201-8.
38. Qiu SD, Young CY, Bilhartz DL, Prescott JL, Farrow GM, He WW, et al. In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol 1990;144:1550-6.
39. Pretlow TG, Pretlow TP, Yang B, Kaetzel CS, Delmoro CM, Kamis SM, et al. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int J Cancer 1991;49:645-9.
40. Hakalahti L, Vihko P, Henttu P, Autio-Harmainen H, Soini Y, Vihko R. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int J Cancer 1993;55:590-7.
41. Lilja H. Significance of different molecular forms of PSA. The free, non-complexed form of PSA versus that complexed to alpha I-antichymotrypsin. Urol Clin North Am 1993;20:681-6.
42. Kanely H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993;77: 229-33.
43. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
44. Fair WR, Parrish RF. Antibacterial substances in prostatic fluid. Prog Clin Biol Res 1981;75A:247-64.
45. Fair WR, Wehner N. The prostatic antibacterial factor: identity and significance. Prog Clin Biol Res 1976;6:383-403.
46. Whelan P, Walker BE, Kelleher J. Zinc, vitamin A and prostatic cancer. Br J Urol 1983;55:525-8.
47. Muntzing J, Nilsson T, Polacek J. Zinc and beta-glucuronidase in the human prostate. Scand J Urol Nephrol 1974;8:87-90.
48. Lahtonen R. Zinc and cadmium concentration in whole tissue and in separated epithelium and stroma from human benign prostatic hypertrophic glands. Prostate 1985;6:177-83.
49. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057-68.
50. Wang MH, Gonias SL, Skeel A, Wolf BB, Yoshimura T, Leonard EJ. Proteolytic activation of single-chain precursor macrophage-stimulating protein by nerve growth factor-gamma and epidermal growth factor-binding protein, members of the kallikrein family. J Biol Chem 1994;269: 13806-10.
51. Meakin SO, Shooter EM. The nerve growth factor family of receptors. Trends Neurosci 1992;15:323-31.
52. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991;73:401-7.
53. Baniel J, Adlington RM, Becker GW, Goode RL, Leibovitch IY, McCoull W, et al. Prostate-specific antigen (PSA)-mediated stimulation of DU-145 human prostatic cancer (PCa) cells and inhibition of this response by LY312340, an inhibitor of PSA serine protease activity [abstract]. Proc Am Assoc Cancer Res 1998;39:430.